Synonyms: Kimyrsa® | LY-333328 | LY333328 | Orbactiv®
oritavancin is an approved drug (FDA (2014), EMA (2015))
Compound class:
Synthetic organic
Comment: Oritavancin is a semi-synthetic glycopeptide antibacterial drug [1]. It is structurally related to vancomycin, and likewise is active against several Gram-positive organisms including methicillin resistant Staphylococcus aureus (MRSA). Like dalbavancin, it offers the option of single-dose administration.
|
|
References |
1. Arhin FF, Draghi DC, Pillar CM, Parr Jr TR, Moeck G, Sahm DF. (2009)
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother, 53 (11): 4762-71. [PMID:19738026] |
2. Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W, SOLO I and SOLO II investigators. (2018)
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Antimicrob Agents Chemother, 62 (4). [PMID:29358292] |
3. Deck DH, Jordan JM, Holland TL, Fan W, Wikler MA, Sulham KA, Ralph Corey G. (2016)
Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting. Infect Dis Ther, 5 (3): 353-61. [PMID:27370913] |